Neutrophil elastase inhibitors as treatment for COPD

Bibliography

• WORLD HEALTH ORGANIZATION: World Health Report 2000. Geneva, World Health Organization (2000).
   Google Scholar
• MURRY CJ, LOPEZ AD: Regional patterns of disability-free life expectancy and disability-adjusted life expectancy: global Burden of Disease Study. Lancet (1997) 349(9062):1347–1352.
   PubMed Web of Science ®Google Scholar
• MURRY CJ, LOPEZ AD: Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997 349(9063):1436–1442.
   PubMed Web of Science ®Google Scholar
• PAUVVELS R: Global initiative for chronic obstructive lung diseases (GOLD): time to act. Eur. Resp. (2001) 18(0:901–902
   PubMed Web of Science ®Google Scholar
• GLOBAL INITIATIVE FOR CHRONICOBSTRUCTIVE LUNG DISEASE: Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. MHLBI/WHO workshop report. Bethesda, National Heart, Lung and Blood Institute, (2001) NIH Publication No. 2701:1–100.
   Google Scholar
• LECKIE MJ, BRYAN SA, HANSEL TT: Novel therapy for COPD. Expert Opin. Investig. Drugs (2000) 9(1):3–23.
   PubMed Web of Science ®Google Scholar
• ••A splendid review of novel therapy forCOPD.
   Google Scholar
• BARNES PJ: Future advances in COPD therapy. Respiration (2001) 68(0:441–448.
   PubMed Web of Science ®Google Scholar
• FLETCHER CM, PRIDE NB: Definition of emphysema, chronic bronchitis, asthma and airflow obstruction. : twenty-five years on from the CIBRA symposium. Thorax (1984) 39:81–85.
   Google Scholar
• REID L: The pathology of obstructive and inflammatory airway diseases. Eur: Resp. Dis. Sapp] (1986) 147:26–37.
   PubMedGoogle Scholar
• BUIST AS: Current status of small airways disease. Chest (1984) 86(1):100–105.
   PubMed Web of Science ®Google Scholar
• SNIDER GL: Chronic obstructive pulmonary disease: risk factors, pathophysiology and pathogenesis. Ann. Rev Med. (1989) 40:411–429.
   PubMed Web of Science ®Google Scholar
• THOMPSON AB, DAUGHTON D, ROBBINS RA et al.: Intramural airway inflammation in chronic bronchitis. Characterization and correlation with clinical parameters. Am. Rev Respir: Dis. (1989) 140(0:1527–1537.
   PubMed Web of Science ®Google Scholar
• SAETTA M, DI STEFANO A, MAESTRELLI P et al.: Activated T- lymphocytes and macrophages in bronchial mucosa of subjects with chronic bronchitis. Am. Rev Respir. Dis. (1993) 147(4301–306.
   Web of Science ®Google Scholar
• BARNES PJ: Mechanisms in COPD, differences from Asthma. Chest (2000) 117(2):10S-14S.
   Google Scholar
• •Review concerning the characterisation of C OPD as different from asthma.
   Google Scholar
• FINKELSTEIN R, FRASER RS, GHEZZO H et al.: Alveolar inflammation and its relation to emphysema in smokers. Am. Respir. Grit. Care Med. (1995) 152(5 Pt 1):1666–1672.
   Google Scholar
• BAGGIOLINI M, WALZ A, KUNKEL SL: Neutrophil-activating peptide- l/interleukin 8, a novel cytokine that activates neutrophils. Clin. Invest. (1989) 84(01045–1049.
   Google Scholar
• NOCKER RE, SCHOONBROOD DF, VAN DE GRAAF EA et al: Interleukin-8 in airway inflammation in patients with asthma and chronic obstructive pulmonary disease. In Arch. Allergy Immunol (1996) 109(4183–191.
   Web of Science ®Google Scholar
• RICHMAN-EISENSTAT JBY, JORENS PG, HÈBERT CA et al.: Interleuldn-8, an important chemoattractant in sputum of patients with chronic inflammatory airway diseases. Am. .1 Physiol (1993) 264(4 Pt 1)1413–L418.
   Google Scholar
• YAMAMOTO C, YONEDA T, YOSHIKAWA M et al.: Airway inflammation in COPD assessed by sputum levels of intreleukin-8. Chest (1997) 112(2):505–510.
   PubMed Web of Science ®Google Scholar
• MIO T, ROMBERGER DJ, THOMPSON AB et al.: Cigarette smoke induces interleukin-8 release from human bronchial epithelial cells. Am. Respir: Crit. Care Med. (1997) 155(0:1770–1776.
   PubMed Web of Science ®Google Scholar
• HUBBARD RC, FELLS G, GADEK J et al: Neutrohil accumulation in the lung in alpha-1-antitrypsin deficiency: spontaneous release of leukotriene B4 by alveolar macrophages.' Clin. Invest. (1991) 88(0:891–897.
   Google Scholar
• KWON 0J, AU BT, COLLINS PD et al: Tumor necrosis factor-induced interleukin-8 expression in cultured human airway epithelial cells. Am. Physiol (1994) 267(4 Pt 1)1398–L405.
   Google Scholar
• BARNES PJ, KARIN M: Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl. Med. (1997) 336(15):1066–1071.
   PubMed Web of Science ®Google Scholar
• BURKE-GAFFNEY A, HELLEWELL PG: Tumour necrosis factor-alpha-induced ICAM-1 expression in human vascular endothelial and lung epithelial cells: modulation by tyrosine kinase inhibitors. Br. Pharmacol (1996) 119(6):1149–1158.
   PubMed Web of Science ®Google Scholar
• WARD PA: Role of complement, chemokines, and regulatory cytokines in acute lung injury. Ann. NY Acad. Sci. (1996) 796:104–112.
   PubMed Web of Science ®Google Scholar
• MCGOWAN SE, MURRAY JJ: Direct effects of neutrophil oxidants on elastase-induced extracellular matrix proteolysis. Am. Rev. Respir: Dis. (1987) 135(6):1286–1293.
   PubMed Web of Science ®Google Scholar
• MCDONALD JA, KELLEY DG: Degradation of fibronectin by human leukocyte elastase. Release of biologically active fragments. J. Biol. Chem. (1980) 225(10:8848–8858.
   Google Scholar
• MAINARDI CL, HASTY DL, SEYERJM et al.: Specific cleavage of human Type III collagen by human polymorphonuclear leukocyte elastase. J. Biol. Chem. (1980) 225(2012006–12010.
   Google Scholar
• BIETH G: Elastase: catalytic and biological properties. In: Regulation of matrix accumulation. Mecham RP (eds). Academic Press, New York, USA (1986):217–306.
   Google Scholar
• JAN OFF A, BLONDIN J: The effect of human granulocyte elastase on bacterial suspensions. Lab. Invest. (1973) 29(0454–457.
   PubMed Web of Science ®Google Scholar
• SANDHAUS RA: Elastase may play a central role in neutrophil migration through connective tissue. In: Pulmonary emphysema and proteolysis. Taylar JC, Mittman C (eds). New York Academic Press (1987):227–233.
   Google Scholar
• SINHA S, WATOREK W, KARR S et al.: Primary structure of human neutrophil elastase. Proc. Natl. Acad. Sci. USA (1987) 84(0:2228–2232.
   PubMed Web of Science ®Google Scholar
• BODE W, MEYER E JR, POWERS JC: Human leukocyte and porcine pancreatic elastase: X-ray crystal structures, mechanism, substrate specificity, and mechanism-based inhibitors. Biochemistry (1989) 28(5): 1951–1963.
   PubMed Web of Science ®Google Scholar
• TRAVIS J, DUBIN A, POTEMPA Jet al.: Neutrophil proteinases. Ann. NY Acad. Sci. (1991) 624:81–86.
   PubMed Web of Science ®Google Scholar
• TETLEY TD: New perspectives on basic mechanism in lung disease. 6. Proteinase imbalance: its role in lung disease. Thorax (1993) 48(0:560–565.
   Google Scholar
• STOCKLEY RA: Neutrophils and Protease/ antiprotease imbalance. Am. Rev Respir: Dis. (1999) 160(5 Pt 4549–552.
   Web of Science ®Google Scholar
• AMITANI R, WILSON R, RUTMAN A: Effects of human neutrophil elastase and Pseudomonas aeruginosa proteinases on human respiratory epithelium. Am. j Respir: Cell Mol Biol. (1991) 4(1):26–32.
   PubMed Web of Science ®Google Scholar
• GOLDMAN G, WELBOURN R, KOBZIK L et al: Reactive oxygen species and elastase mediate lung permeability after acid aspiration. J. Appl Physiol (1992) 73(2):571–575.
   PubMed Web of Science ®Google Scholar
• NADEL J: Role of mast cell and neutrophil proteases in airway secretion. Am. Rev Respir. Dis. (1991) 144(3 Pt 2):S48–S51.
   Google Scholar
• FAHY JV, SCHUSTER A, UEKI I et al: Mucus hypersecretion in bronchiectasis. The role of neutrophil proteases. Am. Rev Respir. Dis. (1992) 146(6):1430–1433.
   PubMed Web of Science ®Google Scholar
• SNIDER GL, LUCEY EC, CHRISTENSEN TG et al.: Emphysema and bronchial secretory cell metaplasia induced in hamsters by human neutrophil products. Am. Rev Respic Dis. (1984) 129(1):155–160.
   PubMed Web of Science ®Google Scholar
• SMALLMAN TA, HILL SL, STOCKLEY RA: Reduction of ciliary beat frequency in vitro by sputum from patients with bronchiectasis: a serine proteinase effect. Thorax (1984) 39(9):663–667.
   PubMed Web of Science ®Google Scholar
• O'RIORDAN TG, OTERO R, MAO Y et al.: Elastase contributes to antigen-induced mucociliary dysfunction in ovine airways. Am. J. Respir. Grit. Care Med. (1997) 155(5):1522–1528.
   Google Scholar
• REPINE JE, BAST A, LANKHORST I et al.: Oxidative stress in chronic obstructive pulmonary disease. Am. Rev. Respic Dis. (1997) 156(2 Pt 1):341–357.
   Google Scholar
• MACNEE W: Oxidants/Antioxidants and COPD. Chest (2000) 117(5): 303S-317S.
   Google Scholar
• •Review concerning the imbalance between oxidants and antioxidants in COPD.
   Google Scholar
• PICCIONI PD, KRAMPS JA, BASBAUM CB et al.: Proteinase/proteinase inhibitor imbalance in sputum sol phases from patients with chronic obstructive pulmonary disease. Suggestions for a key role played by antileukoprotease. Chest (1992) 102(5):1470–1476.
   Google Scholar
• STOCKLEY RA, BURNETT D: Alphal-antitrypsin and leukocyte elastase in infected and noninfected sputum. Am. Rev Respir. Dis. (1979) 120(5):1081–1086.
   PubMed Web of Science ®Google Scholar
• SNIDER GL, LUCEY EC, CHRISTENSEN TG et al.: Emphysema and bronchial secretory cell metaplasia induced in hamsters by human neutrophil products. Am. Rev Respic Dis. (1984) 129(1):155–160.
   PubMed Web of Science ®Google Scholar
• ERIKSSON S: Pulmonary emphysema and alphal-antitrypsin deficiency. Acta. Med. Scand. (1964) 175:197–205.
   PubMed Web of Science ®Google Scholar
• NIEWOEHNER DE: Cigarette smoking, lung inflammation, and the development of emphysema. j. Lab. Clin. Med. (1988) 111(1): 15–27.
   PubMed Web of Science ®Google Scholar
• HAUTAMAKI RD, KOBAYASHI DK, SENIOR RM et al.: Requirement for macrophage elastase for cigarette smoke-induced emphysema in mice. Science (1997) 277(5334):2002–2004.
   PubMed Web of Science ®Google Scholar
• •An experimental report studying macrophage elastase-mediated emphysema.
   Google Scholar
• OFULUE AF, KO M: Effects of depletion of neutrophils or macrophages on development of cigarette smoke-induced emphysema. Am. Physiol (1999) 277(1 Pt 1):L97–L105.
   Google Scholar
• KLUT ME, DOERSCHUK CM, VAN EEDEN SF et al.: Activation of neutrophils within pulmonary microvessels of rabbits exposed to cigarette smoke. Am. Respic Cell Ma Biol. (1993) 9(1):82–89.
   Google Scholar
• TERASHIMA T, KLUT ME, ENGLISH D et al: Cigarette smoking causes sequestration of polymorphonuclear leukocytes released from the bone marrow in lung microvessels. Am. J. Respic Cell Ma Biol. (1999) 20(1):171–177.
   PubMed Web of Science ®Google Scholar
• DHAMI R, GILKS B, XIE C et al: Acute cigarette smoke-induced connective tissue breakdown is mediated by neutrophils and prevented by alphal-antitrypsin. Respic Cell Mol Biol. (2000) 22(2):244–252.
   PubMed Web of Science ®Google Scholar
• MARCH TH, BARR EB, FINCH GL et al: Cigarette smoke exposure produces more evidence of emphysema in B6C3F1 mice than in F344 rats. Toxica Sci. (1999) 51(2):289–299.
   PubMed Web of Science ®Google Scholar
• MOLHUIZEN HO, SCHALKWIJK J.: Structural, biochemical, and cell biological aspects of the serine proteinase inhibitor SKALP/elafin/ESI. Biol. Chem. Hoppe-Seyler. (1995) 376(1):1–7.
   Google Scholar
• WENCKER M, FUHRMANN B, BANIK N et al.: Longitudinal follow-up of patients with al-protease inhibitor deficiency before and during therapy with IV with al-protease inhibitor. Chest (2001) 119(3):737–744.
   PubMed Web of Science ®Google Scholar
• SALLENAVE JM, SI-TA HAR M, COX G et al: Secretory leukocyte proteinase inhibitor is a major leukocyte elastase inhibitor in human neutrophils.j Leukoc. Biol. (1997) 61(6):695–702.
   Google Scholar
• DE WATER R, WILLEMS LN, VAN MUIJEN GN et al.: Ultrastructural localization of bronchial antileukoprotease in central and peripheral human airways by a gold-labeling technique using monoclonal antibodies. Am. Rev Respic Dis. (1986) 133(5):882–890.
   Google Scholar
• WRIGHT CD, HAVILL AM, MIDDLETON SC et al: Secretory leukocyte protease inhibitor prevents allergen-induced pulmonary responses in animal models of asthma. I Pharmacol Exp. The]: (1999) 289(2):1007–1014.
   PubMed Web of Science ®Google Scholar
• SUZUKI T, WANG W, LIN JT et al: Aerosolized human neutrophil elastase induces airway constriction and hyperresponsiveness with protection by intravenous pretreatment with half-length secretory leukoprotease inhibitor. Am. Respir. Crit. Care Med. (1996) 153(4 Pt 1):1405–1411.
   Google Scholar
• BINGLE L, TETLEY TD: Secretory leukoprotease inhibitor: partnering alpha 1-proteinase inhibitor to combat pulmonary inflammation. Thorax (1996) 51(12):1273–1274.
   PubMed Web of Science ®Google Scholar
• TOMEE JF, KOETER GH, HIEMSTRA PSet al.: Secretory leukoprotease inhibitor: a native antimicrobial protein presenting a new therapeutic option? Thorax (1998) 53:114–116
   Google Scholar
• WIEDOW 0, SCHRODER JM, GREGORY H et al.: Elafin: an elastase-specific inhibitor of human skin. Purification, characterization, and complete amino acid sequence. Biol. Chem. (1990) 265(25):14791–14795.
   Google Scholar
• NARA K, ITO S, ITO T et al: Elastase inhibitor elafin is a new type of proteinase inhibitor which has a transglutaminase-mediated anchoring sequence termed `cementoin'. Biochem. (1994) 115(3):441–448.
   Web of Science ®Google Scholar
• BINGLE L, TETLEY TD, BINGLE CD: Cytokine-mediated induction of the human elafin gene in pulmonary epithelial cells is regulated by nuclear factor-kappaB. Am. Respir. Cell Mol Biol. (2001) 25(1):84–91.
   PubMed Web of Science ®Google Scholar
• SALLENAVE JM, SHULMANN J, CROSSLEY J et al.: Regulation of secretory leukocyte proteinase inhibitor (SLPI) and elastase-specific inhibitor (ESI/elafin) in human airway epithelial cells by cytokines and neutrophilic enzymes. Am. I Respic Cell Mol Biol. (1994) 11(6):733–741.
   PubMed Web of Science ®Google Scholar
• TANAKA N, FUJIOKA A, TAJIMA S et al: Elafin is induced in epidermis in skin disorders with dermal neutrophilic infiltration: interleukin-1 beta and tumour necrosis factor-alpha stimulate its secretion M vitro. Br. Dermatol (2000) 143(4):728–732.
   PubMed Web of Science ®Google Scholar
• REID PT, MARSDEN ME, CUNNINGHAM GA et al: Human neutrophil elastase regulates the expression and secretion of elafin (elastase-specific inhibitor) in Type II alveolar epithelial cells. FEBS Lett. (1999) 457(1):33–37
   PubMed Web of Science ®Google Scholar
• SIMPSON AJ, MAXWELL Al, GOVAN JR et al.: Elafin (elastase-specific inhibitor) has anti-microbial activity against Gram-positive and Gram-negative respiratory pathogens. FEBS Lett. (1999) 452(3):309–313.
   PubMed Web of Science ®Google Scholar
• DELACOURT C, HERIGAULT S, DELCLAUX C et al.: Protein against acute lung injury by intravenous or intratracheal pretreatment with EPI-HNE-4, a new potent neutrophil elastase inhibitor. Am. J. Respic Cell Ma Biol. (2002) 26(3):290–297.
   PubMed Web of Science ®Google Scholar
• BRADBURY J: Neutrophil elastase inhibitors for cystic fibrosis. Drug Discovery Today (2001) 6(9):441–442.
   PubMed Web of Science ®Google Scholar
• BERNSTEIN PR, EDWARDS PD, WILLIAMS JC: Inhibitors of human leukocyte elastase. In Progress M Medicinal Chemistry Ellis GP, Luscombe DK (eds). Elsevier Science (1994):59–120.
   Google Scholar
• •A thorough review of proteinase inhibitors.
   Google Scholar
• IMAKI K, OKADA T, NAKAYAMA Yet al.: Non-peptidic inhibitors of human neutrophil elastase: the design and synthesis of sulfonanilide-containing inhibitors. Bioorg. Med. Chem. (1996) 4(12):2115–2134.
   Google Scholar
• KAWABATA K, SUZUKI M, SUGITANI M et al.: ONO-5046, a novel inhibitor of human neutrophil elastase. Biochem. Biophys. Res. Commun. (1991) 177(2):814–820.
   PubMed Web of Science ®Google Scholar
• •The first in vivo and in vitro pharmacological study of ONO-5046.
   Google Scholar
• KAWABATA K, HAGIO T, MATSUMOTO S et al.: Effect of specific neutrophil elastase inhibitor, ONO-5046 on phorbol myristate acetate-induced acute lung injury in rabbit. Inflamm. Res. (1995) 44 (Suppl. 3):5269.
   Google Scholar
• WANG HG, SHIBAMOTO T, MIYAHARA T et al.: Effect of ONO-5046, a specific neutrophil elastase inhibitor, on the Phorbol myristate acetate-induced injury in isolated dog lung. Exp. Lung Res. (1999) 25(1):55–67.
   PubMed Web of Science ®Google Scholar
• YASUI S, NAGAI A, AOSHIBA K et al.: A specific neutrophil elastase inhibitor (ONO-5046.Na) attenuates LPS-induced acute lung inflammation in the hamster. Ear: Respic (1995) 8(8):1293–1299.
   Google Scholar
• UCHIBA M, OKAJIMA K, MURAKAMI K et al.: Attenuation of endotoxin-induced pulmonary vascular injury by antithrombin III. Am. J. Physic] (1996) 270(14)1921–L930.
   Google Scholar
• MURAKAMI K, OKAJIMA K, UCHIBA M et al.: Activated protein C attenuates endotwdn-induced pulmonary vascular injury by inhibiting activated leukocytes in rats. Blood (1996) 87(2):642–647.
   PubMed Web of Science ®Google Scholar
• GUO L, YAMAGUCHI Y, IKEI Set al.: Neutrophil elastase inhibitor (ONO-5046) prevents lung hemorrhage induced by lipopolysaccharide in rat model of cerulein pancreatitis. Dig. Dis. Sci. (1995) 40(10:2177–2183.
   Google Scholar
• SAKAMAKI F, ISHIZAKA A, URANO T et al.: Effect of a specific neutrophil elastase inhibitor, ONO-5046, on endotoxin-induced acute lung injury. Am. I Respic Crit. Care Med. (1996) 153 (1):391–397.
   PubMed Web of Science ®Google Scholar
• TAOOKA Y, MAEDA A, HIYAMA K et al.: Effects of neutrophil elastase inhibitor on bleomycin-induced pulmonary fibrosis in mice. Am. J. Respir. Grit. Care. Med. (1997) 156(1):260–265.
   PubMed Web of Science ®Google Scholar
• KUBO K, KOBAYASHI T, HAYANO T et al.: Effects of ONO-5046, a specific neutrophil elastase inhibitor, on endotoxin-induced lung injury in sheep. I Appl. Physiol (1994) 77(3):1333–1340.
   PubMed Web of Science ®Google Scholar
• MURAKAMI K, OKAJIMA K, UCHIBA M et al.: Gabexate mesilate, a synthetic protease inhibitor, attenuates endotoxin-induced pulmonary vascular injury by inhibiting tumor necrosis factor production by monocytes. Crit. Care Med. (1996) 24(6):1047–1053.
   PubMed Web of Science ®Google Scholar
• NISHINA K, MIKAWA K, TAKAO Yet al.: ONO-5046, an elastase inhibitor, attenuates endotoxin-induced acute lung injury in rabbits. Anesth. Analg. (1997) 84(5):1097–1103.
   Google Scholar
• SAKAMAKI F, ISHIZAKA A, URANO T et al.: Effect of a specific neutrophil elastase inhibitor, ONO-5046, on endotoxin-induced acute lung injury. Am. I Respic Crit. Care Med. (1996) 153 (1):391–397.
   PubMed Web of Science ®Google Scholar
• KINOSHITA M, ONO S, MOCHIZUKI H: Neutrophils mediate acute lung injury in rabbits: role of neutrophil elastase. Eur. Surg. Res. (2000) 32(6):337–346.
   PubMed Web of Science ®Google Scholar
• KANEKO K, KUDOH I, HATTORI S et al.: Neutrophil elastase inhibitor, ONO-5046, modulates acid-induced lung and systemic injury in rabbits. Anesthesiology (1997) 87(3):635–641.
   PubMed Web of Science ®Google Scholar
• HAGIO T, KAWABATA K, MASTUMOTO S et al.: A specific neutrophil elastase inhibitor, ONO-5046Na prevents acid aspiration-induced lung injury in hamster. Mediator Inflamm. (1999) 8\(Suppl. 1):5103.
   Google Scholar
• YOSHIMURA K, NAKAGAWA S, KOYAMA S et al: Roles of neutrophil elastase and superoxide anion in leukotriene B4-induced lung injury in rabbit. I Appl Physic] (1994) 76(1):91–96.
   PubMed Web of Science ®Google Scholar
• YOSHITAKE K, ISOHAMA Y, KAI H et al.: Substance P stimulates the loss of cell-associated high molecular weight glycoconjugates from cultured hamster tracheal epithelial cells through polymorphonuclear leucocytes activation. Biochem. MM. Biol. Int. (1995) 36(5):1009–1016.
   PubMedGoogle Scholar
• TAKEYAMA K, TAMAOKI J, KONNO K et al.: Effect of a neutrophil elastase inhibitor on NAP-1/IL-8-induced stimulation of goblet cell secretion in guinea pig airways. Eur. Respic J. (1994) 7\(Suppl. 18):765.
   Google Scholar
• NOGAMI H, AIZAWA H, MATSUMOTO K et al: Neutrophil elastase inhibitor, ONO-5046 suppresses ozone-induced airway mucus hypersecretion in guinea pigs. Ear: J. Pharmacol (2000) 390(1-2):197–202.
   PubMed Web of Science ®Google Scholar
• LUISETTI M, PICCIONI PD, DONNINI M et al.: Studies of MR889, a new synthetic proteinase inhibitor. Biochem. Biophys. Res. Commun. (1989) 165(2):568–573.
   PubMed Web of Science ®Google Scholar
• BAICI A, PELLOSO R, HORLER D: The kinetic mechanism of inhibition of human leukocyte elastase by MR889, a new cyclic thiolic compound. Biochem. Pharrmacol. (1990) 39(5):919–924.
   PubMed Web of Science ®Google Scholar
• RIZZI M, CASALE E, ASCENZI P: Crystal structure and NMR investigation of the serine proteinase inhibitor MR889, a cyclic thiolic compound. I Chem. Soc. Perkin. Trans. 2 (1993) 11:2253–2256.
   Google Scholar
• RIZZI M, CASALE E, CODA A et al: Serine proteinase inhibition by cyclic thiolic compound Y53025: a crystallographic study. Biochem. Int. (1992) 28(3):385–392.
   PubMedGoogle Scholar
• CARUGO KD, RIZZI M, FASANO M et al.: Inhibition of serine proteinases belonging to the chymotrypsin superfamily by the cyclic thiolic compound Y53025: a comparative crystallographic study. Biochem. Biophys. Res. Commun. (1993) 193(1):32–39.
   PubMed Web of Science ®Google Scholar
• MORETTI M, GORRINI M, DONNETTA AM et al: Effects of MR889, a cyclic thiolic neutrophil elastase inhibitor, on rheologic properties of mucus. Life Sci. (1994) 54(7):463–469.
   PubMed Web of Science ®Google Scholar
• LUISETTI M, STURANI C, SELLA D et al.: MR889, a neutrophil elastase inhibitor, in patients with chronic obstructive pulmonary disease: a double-blind, randomized, placebo-controlled clinical trial. Eur. Resp. J. (1996) 9(7):1482–1486.
   PubMed Web of Science ®Google Scholar
• CVETOVICH RJ, CHARTRAIN M, HARTNER FW JR et al.: An asymmetric synthesis of L-694,458, a human leukocyte elastase inhibitor, via novel enzyme revolution of P-lactam esters. Org. Chem. (1996) 61(19):6575–6580.
   Google Scholar
• VINCENT SH, PAINTER SK, LUFFER-ATLAS D et al.: Orally active inhibitors of human leukocyte elastase. II. Disposition of L-694,458 in rats and rhesus monkeys. Drug Metab. Dispos. (1997) 25(8):932–939.
   Google Scholar
• DWYER TM, FARLEY JM: Human neutrophil elastase releases two pools of mucinlike glycoconjugate from tracheal submucosal gland cells. Am. J. Physiol Lung Cell Mol Physiol (2000) 278(4)1675–L682.
   Google Scholar
• BIALECKI RA: IBC's conference on pulmonary hypertension: New understanding for therapeutic development. Expert Opin. Investig. Drugs (1998) 7:653–658.
   PubMedGoogle Scholar
• PATTON LM: In vivo evaluation of MDL 201,404YA, a novel inhibitor of human neutrophil elastase. Agents and Actions Sapp]. (1993) 42:83–96.
   PubMedGoogle Scholar
• FOLKESSON HG: CE-1037 Cortech. Carr. Opin. Anti -inflammatory Immunomodulatory Invest. Drugs (2000) 2:133–141.
   Google Scholar
• •Review concerning CE-1037.
   Google Scholar
• FDC REPORTS PINK SHEET: United Therapeutics Telemedicine to support pulmonary hypertension trial. (1999) 61:21–22.
   Google Scholar
• MACDONALD SJ, DOWLE MD, HARRISON LA et al.: The discovery of a potent, intracellular, orally bioavailable, long duration inhibitor of human neutrophil elastase-GW311616A a development candidate. Bioorg. Med. Chem. Lett. (2001) 11(7):895–898.
   PubMed Web of Science ®Google Scholar
• MITSUHASHI H, NONAKA T, HAMAMURA I et al.: Pharmacological activities of TEI-8362, a novel inhibitor of human neutrophil elastase. Br. J. Pharmacol (1999) 126(5):1147–1152.
   PubMed Web of Science ®Google Scholar
• OHBAYASHI H: Current synthetic inhibitors of human neutrophil elastase. Expert Opin. Titer. Patents (2002) 12(1):65–84.
   Web of Science ®Google Scholar
• •Review concerning novel HNE inhibitors and patents.
   Google Scholar
• OHMOTO K, YAMAMOTO T, OKUMA M et al.: Development of orally active nonpeptidic inhibitors of human neutrophil elastase. J. Med. Chem. (2001) 44(8):1268–1285.
   PubMed Web of Science ®Google Scholar
• OHMOTO K, YAMAMOTO T, HORIUCHI T et al.: Design and Synthesis of new orally active nonpeptidic inhibitors of human neutrophil elastase. J. Med. Chem. (2000) 43(20:4927–4929.
   PubMed Web of Science ®Google Scholar
• OHMOTO K, OKUMA M, YAMAMOTO T et al.: Design and synthesis of new orally active inhibitors of human neutrophil elastase. Bioorg. Med. Chem. (2001) 9(5):1307–1323.
   PubMed Web of Science ®Google Scholar
• SEKIOKA T, HIROTA Y, NAKAO S et al.: Pharmacological profile of a novel orally active neutrophil elastase inhibitor, ONO-6818. Am."Crit.Care Med. (2001) 163:ATS 2001 abstract.
   Google Scholar
• KUBO T, OKAZAKI H, KUROMIYA A et al: AE-3763, a novel inhibitor of neutrophil elastase (1): Biochemical and pharmacological properties of AE-3763. fpn. Pharmacol (2001) 85:199.
   Google Scholar
• KUROMIYA A, OKAZAKI H, KUBO T et al: AE-3763, a novel inhibitor of neutrophil elastase (2): Effects of AE-3763 on acute organ failure models. Jpn. Pharmacol (2001) 85:199.
   Google Scholar
• SHINGUH Y, IMAI K, YAMAZAKI A et al: Biochemical and pharmacological characterization of FK-706, a novel elastase inhibitor: Eur. Pharmacol. (1997) 337(1):63–71.
   Web of Science ®Google Scholar
• WILLIAMS JC, FALCONE RC, KNEE C et al.: Biologic characterization of ICI-200,880 and ICI-200,355, novel inhibitors of human neutrophil elastase. Am. Rev Resp. Dis. (1991) 144(0875–883.
   PubMed Web of Science ®Google Scholar
• WILLIAMS JC, STEIN RL, GILES RE et al: Biochemistry and pharmacology of ICI-200,880, a synthetic peptide inhibitor of human neutrophil elastase. Ann. NY Acad. Sri. (1991) 624:230–243.
   PubMed Web of Science ®Google Scholar
• WILLIAMS JC, STEIN RL, KNEE C et al: Pharmacologic characterization of ICI 200,880: A novel, potent and selective inhibitor of human neutrophil elastase. FASEB J. (1998) 2:A346, abstract 291.
   Google Scholar
• AUGER WR, MOSER KM, COMITO R et al: Efficacy of intravenous ICI-200,880 in the prevention of adult respiratory distress syndrome (ARDS) in patients undergoing pulmonary thromboendarterectomy. Am. J. Resp. Grit. Care Med. (1994) 149:A1032.
   Google Scholar
• GOTTLIEB JE, ELMER M, STEINER R et al: Efficacy of intravenous ICI-200,880, a neutrophil elastase inhibitor, in the treatment of adult respiratory distress syndrome (ARDS). Chest (1994) 106:67S.
   PubMed Web of Science ®Google Scholar
• VEALE CA, BERNSTEIN PR, BOHNERT CM et al.: Orally active trifluoromethyl ketone inhibitors of human leukocyte elastase. J. Med. Chem. (1997) 40(20:3173–3181.
   PubMed Web of Science ®Google Scholar
• EDWARDS PD, VEALE CA: Inhibitors of human neutrophil elastase. Expert Opin. The]: Patents (1997) 7:17–28.
   Web of Science ®Google Scholar
• •Review concerning novel HNE inhibitors and patents until 1997.
   Google Scholar
• EDWARDS PD, ANDISIK DW, BRYANT CA et al: Discovery and biological activity of orally active peptidyl trifluoromethyl ketone inhibitors of human leukocyte elastase. Med. Chem. (1997) 40(141876–1885.
   Web of Science ®Google Scholar
• HUANG YI, SURICHAMORN W, CAO GL et al.: Effect of trifluoromethyl ketone-based elastase inhibitors on neutrophil function M vitro. J. Leukocyte Biol. (1998) 64(3):322–330.
   PubMed Web of Science ®Google Scholar
• OHBAYASHI H: ZD-0892 AstraZeneca. Carr. Opin. Invest. Drugs (2000) 1(4227–229.
   Google Scholar
• VEALE CA, BERNSTEIN PR, BOHNERT CM et al.: Orally active trifluoromethyl ketone inhibitors of human leukocyte elastase. J. Med. Chem. (1997) 40(20:3173–3181.
   PubMed Web of Science ®Google Scholar
• VESTBO J, SORENSEN T, LANGE P et al.: Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomized controlled trial. Lancet (1999) 353(9167):1819–1823.
   PubMed Web of Science ®Google Scholar
• BURGE PS, CALVERLEY PM, JONES PW et al.: Randomized, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary diseases; the ISOLDE trial. BMJ(2000) 320(7245):1297–1303.
   PubMed Web of Science ®Google Scholar
• THE LUNG HEALTH STUDY RESEARCH GROUP: Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl. J. Med. (2000) 343:1902–1909.
   PubMed Web of Science ®Google Scholar